Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 USD | -0.84% | -1.52% | +0.56% |
Apr. 26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
Apr. 26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
Evolution of the average Target Price on Regeneron Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Regeneron Pharmaceuticals, Inc.
Oppenheimer | |
TD Cowen | |
UBS | |
Goldman Sachs | |
Morgan Stanley | |
RBC Capital Markets | |
Cantor Fitzgerald | |
Deutsche Bank Securities | |
Truist Securities | |
Barclays | |
Piper Sandler | |
Wells Fargo Securities | |
BMO Capital | |
Canaccord Genuity | |
Baird | |
BofA Securities | |
Jefferies & Co. | |
Raymond James | |
WestPark Capital | |
Guggenheim | |
JPMorgan Chase | |
SVB Securities LLC | |
EF Hutton | |
Cowen | |
Evercore ISI | |
Argus | |
Bernstein | |
Benchmark Capital | |
HC Wainwright | |
SVB Leerink | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- REGN Stock
- Consensus Regeneron Pharmaceuticals, Inc.